Artificial intelligence and machine learning (AI/ML) have become indispensable tools for uncovering new drug targets and ways to hit them with small and large molecules of all kinds. Speakers at the recent BioFuture conference looked at Moderna, Inc. and messenger RNA as a case study of how AI/ML tools can and have been applied.
AI/ML’s Pharma Credentials
It’s clear that AI/ML in the biopharma industry is far from being a mere buzzword. GSK plc’s new chief scientific officer, Tony Wood, played a key role in building out the British company’s AI/ML organization such that it now employs 120 experts, making it the biggest in-house AI team among large drug makers. (Also see "GSK’s New Research Chief Begins Leadership With Expanded Genomics/AI Alliance" - Scrip, 18 October, 2022.)
Other big pharma players have opted to partner with smaller companies specializing in AI/ML, making the category a prolific segment of business development. In September, Pfizer Inc
The mRNA pioneer came up in two panels at the 8 November meeting in New York City, one focused on the application of technology in biopharma, namely AI/ML in drug discovery and development, and “TechBio” companies that
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
